H. Hool

Safety and Efficacy of Nivolumab in Patients With Advanced Non-Clear Cell Renal Cell Carcinoma: Results From the Phase IIIb/IV CheckMate 374 Study.

E. Lam, B. Somer, N. Vogelzang, 2020, Clinical genitourinary cancer.

A randomized phase II trial of nab‐paclitaxel and gemcitabine with tarextumab or placebo in patients with untreated metastatic pancreatic cancer

A. Bullock, J. Bendell, J. Dupont, 2019, Cancer medicine.

Neoadjuvant HER2-targeted therapy +/- immunotherapy with pembrolizumab (neoHIP): An open-label randomized phase II trial.

A. Giuliano, A. Bardia, H. McArthur, 2022, Journal of Clinical Oncology.

Results of a randomized phase II trial of an anti-notch 2/3, tarextumab (OMP-59R5, TRXT, anti-Notch2/3), in combination with nab-paclitaxel and gemcitabine (Nab-P+Gem) in patients (pts) with untreated metastatic pancreatic cancer (mPC).

A. Bullock, J. Bendell, J. Dupont, 2017 .